| Chios mastic treatment of patients with active Crohn's disease. | |
MedLine Citation:
|
PMID: 17278198 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To evaluate the effectiveness of mastic administration on the clinical course and plasma inflammatory mediators of patients with active Crohn's disease (CD). METHODS: This pilot study was conducted in patients with established mild to moderately active CD, attending the outpatient clinics of the hospital, and in healthy controls. Ten patients and 8 controls were recruited for a 4-wk treatment with mastic caps (6 caps/d, 0.37 g/cap). All patients successfully completed the protocol. CD Activity Index (CDAI), Nutritional Risk Index (NRI), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemotactic protein-1 (MCP-1), and total antioxidant potential (TAP) were evaluated in the plasma at baseline and at the end of the treatment period. Results were expressed as mean values +/- SE and P < 0.05 was considered to indicate statistical significance. RESULTS: Patients exhibited significant reduction of CDAI (222.9 +/- 18.7 vs 136.3 +/- 12.3, P = 0.05) as compared to pretreament values. Plasma IL-6 was significantly decreased (21.2 +/- 9.3 pg/mL vs 7.2 +/- 2.8 pg/ mL, P = 0.027), and so did CRP (40.3 +/- 13.1 mg/mL vs 19.7 +/- 5.5, P = 0.028). TAP was significantly increased (0.15 +/- 0.09 vs 0.57 +/- 0.15 mmol/L uric acid, P = 0.036). No patient or control exhibited any kind of side effects. CONCLUSION: The results suggest that mastic significantly decreased the activity index and the plasma levels of IL-6 and CRP in patients with mildly to moderately active CD. Further double-blind, placebo-controlled studies in a larger number of patients are required to clarify the role of this natural product in the treatment of patients with CD. |
Authors:
|
Andriana C Kaliora; Maria G Stathopoulou; John K Triantafillidis; George V Z Dedoussis; Nikolaos K Andrikopoulos |
Related Documents
:
|
20572418 - Endothelial function in patients with post-cpap residual sleepiness. 12627008 - Correlation between transcranial interleukin-6 gradient and outcome in patients with ac... 16859588 - Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell art... 11277348 - C-reactive protein values and erythrocyte sedimentation rates after total hip and total... 21843538 - Neural correlates of the processing of self-referent emotional information in bulimia n... 9488068 - Transversely tubularized ileal segments for the mitrofanoff or malone antegrade colonic... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: World journal of gastroenterology : WJG Volume: 13 ISSN: 1007-9327 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-02-05 Completed Date: 2007-03-27 Revised Date: 2014-09-07 |
Medline Journal Info:
|
Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China |
Other Details:
|
Languages: eng Pagination: 748-53 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adolescent Adult Aged Crohn Disease / drug therapy*, immunology Female Humans Male Middle Aged Phytotherapy* Pilot Projects Pistacia* Plant Preparations / administration & dosage*, adverse effects Remission Induction Resins, Plant / administration & dosage*, adverse effects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Plant Preparations; 0/Resins, Plant; 61789-92-2/gum mastic |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of age on outcome of total laparoscopic fundoplication for gastroesophageal reflux disease...
Next Document: Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cy...